A biotech developing DKN-01, an antibody for multiple cancers, with trials in stomach, liver, and gynecologic tumors. Think of it as a precision tool targeting a specific cancer growth signal.
No product revenue; money comes from partnerships like the BeiGene licensing deal for Asia. Net income swung to USD 0.08B in Q2 2026, but that's from deal milestones, not recurring sales—operating losses persist.
DKN-01's DKK1 mechanism is novel, but clinical-stage biotechs face competition from Merck's Keytruda and Bristol Myers Squibb's Opdivo in similar indications. Without approved drugs or proprietary platform, the moat is weak—any setback in trials erases it.
Key events, in time order
None yet
None yet
A past swing trade on $LPTX (now $CYPH) is recalled as a missed opportunity, indicating a negative sentiment regarding its past performance.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
